Citigroup Inc Generation Bio Co. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Generation Bio Co. stock. As of the latest transaction made, Citigroup Inc holds 37,116 shares of GBIO stock, worth $35,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,116

Previous 11,134 233.36%

Holding current value

$35,260

Previous $31,000 193.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.16 - $3.51 $56,121 - $91,196	25,982 Added 233.36%	37,116 $91,000
Q2 2024 Aug 12, 2024	BUY	$2.64 - $4.35 $6,922 - $11,405	2,622 Added 30.8%	11,134 $31,000
Q1 2024 May 10, 2024	BUY	$1.73 - $4.07 $3,530 - $8,306	2,041 Added 31.54%	8,512 $34,000
Q4 2023 Feb 09, 2024	BUY	$0.91 - $3.35 $5,123 - $18,860	5,630 Added 669.44%	6,471 $10,000
Q3 2023 Nov 09, 2023	SELL	$3.65 - $6.9 $50,216 - $94,930	-13,758 Reduced 94.24%	841 $3,000
Q2 2023 Aug 10, 2023	BUY	$3.5 - $5.67 $48,720 - $78,926	13,920 Added 2050.07%	14,599 $80,000
Q1 2023 May 11, 2023	SELL	$3.61 - $7.01 $5,472 - $10,627	-1,516 Reduced 69.07%	679 $2,000
Q4 2022 Feb 09, 2023	SELL	$3.66 - $6.77 $1,123 - $2,078	-307 Reduced 12.27%	2,195 $8,000
Q3 2022 Nov 10, 2022	SELL	$4.68 - $8.34 $12,088 - $21,542	-2,583 Reduced 50.8%	2,502 $13,000
Q2 2022 Aug 10, 2022	SELL	$4.87 - $9.41 $72,251 - $139,606	-14,836 Reduced 74.47%	5,085 $33,000
Q1 2022 May 12, 2022	SELL	$4.16 - $7.76 $385,894 - $719,840	-92,763 Reduced 82.32%	19,921 $146,000
Q4 2021 Feb 10, 2022	BUY	$5.99 - $24.97 $292,659 - $1.22 Million	48,858 Added 76.55%	112,684 $798,000
Q3 2021 Nov 10, 2021	BUY	$20.0 - $27.43 $1.28 Million - $1.75 Million	63,826 New	63,826 $1.6 Million

Others Institutions Holding GBIO

# of Institutions

Shares Held

49.6M

Call Options Held

Put Options Held

View Full List

About Generation Bio Co.

Ticker GBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,011,200
Market Cap $56.1M
Description
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was f...

More about GBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account